Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 18/20 | 0.58 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244050 | 0.83 | SYK (0.61) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL1353335 | 0.81 | SYK (0.80) | SYK | |
| SCHEMBL1353332 | 0.81 | SYK (0.80) | SYK | |
| SCHEMBL1852111 | 0.81 | SYK (0.61) | SYK | |
| SCHEMBL10242632 | 0.79 | SYK (0.78) | SYK | |
| SCHEMBL1355118 | 0.79 | SYK (0.82) | SYK | |
| SCHEMBL13624871 | 0.77 | SYK (0.67) | SYKZAP70KCNH2AURKBMAPK8 | |
| SCHEMBL13624874 | 0.77 | SYK (0.72) | SYK | |
| SCHEMBL13624991 | 0.76 | SYK (0.68) | SYKZAP70KCNH2AURKBMAPK8 | |
| SCHEMBL10241568 | 0.76 | SYK (0.65) | SYKZAP70KCNH2AURKBMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2009136995-A2 | INHIBITORS OF SYK PROTEIN KINASE | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | SYK 702/4885ZAP70 2404/4885KCNH2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.